These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33209978)

  • 1. Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8
    Ring SS; Królik M; Hartmann F; Schmidt E; Ali OH; Ludewig B; Kochanek S; Flatz L
    Mol Ther Oncolytics; 2020 Dec; 19():179-187. PubMed ID: 33209978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication-Deficient Lymphocytic Choriomeningitis Virus-Vectored Vaccine Candidate for the Induction of T Cell Immunity against
    Belnoue E; Vogelzang A; Nieuwenhuizen NE; Krzyzaniak MA; Darbre S; Kreutzfeldt M; Wagner I; Merkler D; Lambert PH; Kaufmann SHE; Siegrist CA; Pinschewer DD
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269842
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen.
    Haq K; Jia Y; Elahi SM; MacLean S; Akache B; Gurnani K; Chattopadhyay A; Nazemi-Moghaddam N; Gilbert R; McCluskie MJ; Weeratna RD
    Vaccine; 2019 Nov; 37(47):7029-7040. PubMed ID: 31506193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.
    Xiao H; Peng Y; Hong Y; Liu Y; Guo ZS; Bartlett DL; Fu N; He Y
    J Immunol; 2011 Aug; 187(4):1788-96. PubMed ID: 21746967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
    Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
    PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
    Zhai Y; Yang JC; Spiess P; Nishimura MI; Overwijk WW; Roberts B; Restifo NP; Rosenberg SA
    J Immunother; 1997 Jan; 20(1):15-25. PubMed ID: 9101410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer.
    Dai MS; Vassaux G; Xu M; You RI; Hsieh YF; Ouisse LH; Lo KY; Sytwu HK; Chao TY
    Vaccine; 2012 Nov; 30(48):6903-11. PubMed ID: 22982404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient control of chronic LCMV infection by a CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model.
    He R; Yang X; Liu C; Chen X; Wang L; Xiao M; Ye J; Wu Y; Ye L
    Cell Mol Immunol; 2018 Sep; 15(9):815-826. PubMed ID: 28287115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations.
    Wingerath J; Ostroumov D; Woller N; Manns MP; Pinschewer DD; Orlinger K; Berka U; Kühnel F; Wirth TC
    Mol Ther; 2017 Nov; 25(11):2533-2545. PubMed ID: 28803862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.
    Näslund TI; Uyttenhove C; Nordström EK; Colau D; Warnier G; Jondal M; Van den Eynde BJ; Liljeström P
    J Immunol; 2007 Jun; 178(11):6761-9. PubMed ID: 17513723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development.
    Desjardins D; Huret C; Dalba C; Kreppel F; Kochanek S; Cosset FL; Tangy F; Klatzmann D; Bellier B
    J Gene Med; 2009 Apr; 11(4):313-25. PubMed ID: 19248137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
    Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
    Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.
    Hu Z; Jiang W; Gu L; Qiao D; Shu T; Lowrie DB; Lu SH; Fan XY
    J Mol Med (Berl); 2019 Dec; 97(12):1685-1694. PubMed ID: 31786669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8⁺ T Cells that Protect Against Subcutaneous B16-OVA Melanoma.
    Stark FC; McCluskie MJ; Krishnan L
    Vaccines (Basel); 2016 Nov; 4(4):. PubMed ID: 27869670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
    Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
    Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.
    Peng S; Qiu J; Yang A; Yang B; Jeang J; Wang JW; Chang YN; Brayton C; Roden RBS; Hung CF; Wu TC
    Cell Biosci; 2016; 6():16. PubMed ID: 26918115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma.
    Qiu Z; Huang H; Grenier JM; Perez OA; Smilowitz HM; Adler B; Khanna KM
    Cancer Immunol Res; 2015 May; 3(5):536-46. PubMed ID: 25633711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
    Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R
    J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.